National Institute of Diabetes and Digestive and Kidney Diseases

PREVISE FUELS GROWTH OF ITS BARRETT'S ESOPHAGUS RISK STRATIFICATION TEST WITH A COMPETITIVE $1.8M SBIR GRANT

Retrieved on: 
Thursday, October 12, 2023

BALTIMORE, Oct. 12, 2023 /PRNewswire/ -- Previse, maker of Esopredict, a clinically available test that analyzes methylation of biomarkers to assess the risk of esophageal cancer developing in patients with Barrett's esophagus and currently provides GI physicians with results within one week, was awarded a prestigious and highly competitive $1.8M Direct to Phase II SBIR (Small Business Innovation Research) grant by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH).

Key Points: 
  • Esopredict™, Previse's Flagship Product, Awarded NIH Direct to Phase II SBIR Grant to Drive Further Studies of Commercially Available Barrett's Esophagus Prognostic Test.
  • Securing the SBIR grant for this project involved Previse collaborating with investigators at Johns Hopkins University School of Medicine to submit intensive research and commercialization plans to the NIH, outlining the path Previse is taking to accelerate the adoption of the Esopredict test.
  • Esopredict is a game-changing assay rooted in highly accurate methylation-based analysis, which empowers gastroenterologists to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in patients with Barrett's esophagus.
  • Previse CEO Daniel Lunz said: "This substantial grant awarded by the NIH underlines the potential impact of Previse's Esopredict assay and methylation technology.

Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

Retrieved on: 
Monday, October 2, 2023

IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors.
  • Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology.
  • Transplant recipients deserve new treatment options with better efficacy and fewer side-effects to help protect their transplanted organs,” said Dr. Kirk.
  • Dr. Kirk has helped pioneer the use of co-stimulation pathway blockade to prevent organ rejection in transplant patients.

National Institute of Health to Fund Preclinical Development of Trethera Lead Drug, TRE-515, for Treatment of Crohn’s Disease

Retrieved on: 
Monday, September 25, 2023

The award provides $400,000 to translate proof-of-principle early research findings of Trethera’s clinical stage first-in-class drug, TRE-515, as an oral therapy for Crohn’s disease.

Key Points: 
  • The award provides $400,000 to translate proof-of-principle early research findings of Trethera’s clinical stage first-in-class drug, TRE-515, as an oral therapy for Crohn’s disease.
  • Crohn’s disease is a chronic, relapsing, inflammatory gastrointestinal disorder that can present with diarrhea, fatigue, severe abdominal pain, and weight loss.
  • Almost 1 million Americans suffer from the disease today, with complications including intestinal fistulas, strictures, and colorectal cancer.
  • The disease is primarily driven by autoreactive CD4 T cells of the patient’s own immune system that target antigens in the gut.

NDRI Receives $3.7 Million Grant from NIH to Continue the Development of NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program

Retrieved on: 
Wednesday, September 6, 2023

This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.

Key Points: 
  • This new three-year award for NDRI’s Human Tissue and Organs for Research Resource (HTORR) Program parent grant extends the NIH’s ongoing funding support for HTORR to 35 consecutive years.
  • The HTORR Program supports investigators across the full spectrum of research with access to normal and diseased human biospecimens.
  • “NDRI is grateful to the NIH for the support of our expanding HTORR program,” said Bill Leinweber, President and CEO of NDRI.
  • This grant renewal includes multiple enhancements such as a new Pilot Program, Pathology Service Options, and a Pathology Consultant Committee.

PLAMECA's QUICKISEN is a Natural Solution to Constipation

Retrieved on: 
Tuesday, September 5, 2023

FORT LAUDERDALE, Fla., Sept. 5, 2023 /PRNewswire/ -- Constipation is a common concern among all Americans. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that constipation is common among all ages and populations in the U.S. Symptoms occur in approximately 16% of the population, with the number of cases rising to 33% among those 60 years and older. Cleveland Clinic adds that constipation most often occurs due to a change in diet or routine — as well as an inadequate intake of fiber.

Key Points: 
  • The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains that constipation is common among all ages and populations in the U.S.
  • Cleveland Clinic adds that constipation most often occurs due to a change in diet or routine — as well as an inadequate intake of fiber.
  • "Sometimes, the simplest solution to constipation is to consume foods with more fibrous content," explains Óscar Fernández, managing director of the health brand PLAMECA.
  • In other words, QUICKISEN won't have the intense effect of those stronger constipation tools.

Avoiding the Unpleasant Side Effects of ED Drugs

Retrieved on: 
Friday, July 28, 2023

NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) puts the number at 30 million men .

Key Points: 
  • NIDDK (the National Institute of Diabetes and Digestive and Kidney Diseases) puts the number at 30 million men .
  • The only problem is that often the solution proposed is to take strong ED medications.
  • Harvard Health reports that ED drugs can leave men with headaches, upset stomachs, rashes, dizziness, diarrhea, and even vision problems.
  • The plethora of side effects undoes much of the positive elements that ED drugs can provide to a man’s quality of life.

Europe Probiotics Market Outlook & Forecasts 2023-2028: Benefitting from the Health-Conscious Boom - Increasing Consumption of Probiotics Post-Covid-19 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 24, 2023

The Europe probiotics market is projected to reach a value of $18.76 billion by 2028 from $12.4 billion in 2022, growing at a CAGR of 7.1%

Key Points: 
  • The Europe probiotics market is projected to reach a value of $18.76 billion by 2028 from $12.4 billion in 2022, growing at a CAGR of 7.1%
    In the Europe probiotics market, EU-5 is the leading regional market.
  • Few global and regional, and local players characterize the Europe probiotics market.
  • As various diseases are increasing, such as cancer, obesity, overweight, diabetes, and others in Europe, the consumption of probiotics is increasing simultaneously.
  • But due to increasing consumer vegetarianism in European countries, the European probiotics market vendors are manufacturing non-dairy-based probiotics.

KayoThera, Inc. Strengthens Financial Position with $5.2 Million in Grant and Expanded Series A Funding, Bringing Total Financial Support to $14 Million

Retrieved on: 
Wednesday, July 19, 2023

The expanded financing was led by Accelerator Life Science Partners (ALSP), who also provided Series A funding for KayoThera.

Key Points: 
  • The expanded financing was led by Accelerator Life Science Partners (ALSP), who also provided Series A funding for KayoThera.
  • With the additional $5.2 million in new equity investments, non-dilutive grant funding, and initial seed funding from the New Jersey Health Foundation , KayoThera’s total financial support to date is $14 million.
  • KayoThera has received grant funding from the National Institutes of Health Small Business Innovation Research (SBIR) program 1,2 and the Andy Hill Cancer Research Endowment (CARE) Fund 3.
  • In addition, KayoThera secured additional Series A financing in an expansion round led by ALSP that also included participation from BioAdvance , Pier 70 Ventures , and WRF Capital .

2023 JDRF Children's Congress Delegates Urge Lawmakers to Support Type 1 Diabetes Research and Access to Affordable Insulin

Retrieved on: 
Tuesday, July 11, 2023

WASHINGTON, July 11, 2023 /PRNewswire/ -- Today, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, urged members of the Senate Appropriations Committee to renew the Special Diabetes Program (SDP) and support policies to ensure insulin is available at an affordable and predictable price. Opened by U.S. Senator Patty Murray (D-WA) and led by U.S. Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH), the hearing took place during the 2023 JDRF Children's Congress, a biennial event that brings over 160 kids and teens living with T1D face-to-face with lawmakers and top decision-makers. The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada.

Key Points: 
  • The youth delegates traveled to Washington, D.C. from across the country and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada.
  • The SDP has accelerated the pace of T1D research through a long-term investment of funding at the National Institutes of Health.
  • We can all agree that there should be research to improve the lives of those with diabetes.
  • Following the hearing, the 2023 JDRF Children's Congress delegates continued their advocacy by meeting with lawmakers in their Capitol Hill offices.

Stars Take the Fight to End Type 1 Diabetes to Capitol Hill for the 2023 JDRF Children's Congress

Retrieved on: 
Wednesday, July 5, 2023

WASHINGTON, July 5, 2023 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is thrilled to announce the lineup for the 2023 JDRF Children's Congress Celebrity Advocate Town Hall. The interactive event will feature questions from Children's Congress delegates, kids, and teens from across the U.S. and JDRF's affiliates in the United Kingdom, Australia, the Netherlands, and Canada, that live with T1D.The town hall will be held Monday, July 10 at the Marriott Marquis in Washington, D.C.  

Key Points: 
  • Adam Schefter of ESPN will serve as moderator.
  • He will be joined by Aaron Kowalski, Ph.D., JDRF CEO, Dr. Griffin Rodgers, Director of the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health, and more than 160 JDRF Children's Congress delegates.
  • The youth delegates will travel to Washington D.C. from across the U.S. and JDRF's international affiliates in the United Kingdom, Australia, the Netherlands, and Canada.
  • What: Jimmy Jam, member of the Rock & Roll Hall of Fame, and type 1 diabetes parent to testify at Senate hearing in support of the Special Diabetes Program and insulin affordability
    When: Tuesday, July 11 at 10 a.m.
    Where: The Dirksen Senate Office Building, 50 Constitution Ave NE, Washington, DC 20002, Room 106
    View original content to download multimedia: https://www.prnewswire.com/news-releases/stars-take-the-fight-to-end-typ...